Prognostic Value of Inflammatory Markers in Idiopathic Recurrent Pericarditis

Ashwin K. Kumar; Abdullah Yesilyaprak; Muhammad M. Furqan; Vardhmaan Jain; Bryce Montane; Massimo Imazio; Tom Kai Ming Wang; Christine L. Jellis; Paul C. Cremer; Allan L. Klein

doi:10.1016/j.jacc.2022.02.016

Prognostic Value of Inflammatory Markers in Idiopathic Recurrent Pericarditis

Ashwin K. Kumar, Abdullah Yesilyaprak, Muhammad M. Furqan, Vardhmaan Jain, Bryce Montane, Massimo Imazio, Tom Kai Ming Wang, Christine L. Jellis, Paul C. Cremer, Allan L. Klein^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	1644-1645
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	79
Issue number	16
DOIs	https://doi.org/10.1016/j.jacc.2022.02.016
State	Published - Apr 26 2022

Funding

Dr Imazio has served on scientific advisory boards for Kiniksa Pharmaceuticals, Ltd, and Swedish Orphan Biovitrum AB. Dr Cremer has received research grants from Novartis Pharmaceuticals and Kiniksa Pharmaceuticals Ltd.; and has served on the scientific advisory board for Kiniksa Pharmaceuticals Ltd. Dr Klein has received a research grant from Kiniksa Pharmaceuticals, Ltd; and has served on scientific advisory boards for Cardiol Therapeutics, Kiniksa Pharmaceuticals, Ltd, Swedish Orphan Biovitrum AB, and Pfizer, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Dr Imazio has served on scientific advisory boards for Kiniksa Pharmaceuticals, Ltd, and Swedish Orphan Biovitrum AB. Dr Cremer has received research grants from Novartis Pharmaceuticals and Kiniksa Pharmaceuticals Ltd.; and has served on the scientific advisory board for Kiniksa Pharmaceuticals Ltd. Dr Klein has received a research grant from Kiniksa Pharmaceuticals, Ltd; and has served on scientific advisory boards for Cardiol Therapeutics, Kiniksa Pharmaceuticals, Ltd, Swedish Orphan Biovitrum AB, and Pfizer, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2022.02.016

Cite this

@article{da1bd91502d54d348c473b3677e717ac,

title = "Prognostic Value of Inflammatory Markers in Idiopathic Recurrent Pericarditis",

author = "Kumar, {Ashwin K.} and Abdullah Yesilyaprak and Furqan, {Muhammad M.} and Vardhmaan Jain and Bryce Montane and Massimo Imazio and Wang, {Tom Kai Ming} and Jellis, {Christine L.} and Cremer, {Paul C.} and Klein, {Allan L.}",

year = "2022",

month = apr,

day = "26",

doi = "10.1016/j.jacc.2022.02.016",

language = "English (US)",

volume = "79",

pages = "1644--1645",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "16",

}

TY - JOUR

T1 - Prognostic Value of Inflammatory Markers in Idiopathic Recurrent Pericarditis

AU - Kumar, Ashwin K.

AU - Yesilyaprak, Abdullah

AU - Furqan, Muhammad M.

AU - Jain, Vardhmaan

AU - Montane, Bryce

AU - Imazio, Massimo

AU - Wang, Tom Kai Ming

AU - Jellis, Christine L.

AU - Cremer, Paul C.

AU - Klein, Allan L.

PY - 2022/4/26

Y1 - 2022/4/26

UR - http://www.scopus.com/inward/record.url?scp=85127866003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127866003&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2022.02.016

DO - 10.1016/j.jacc.2022.02.016

M3 - Letter

C2 - 35450584

AN - SCOPUS:85127866003

SN - 0735-1097

VL - 79

SP - 1644

EP - 1645

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 16

ER -

Prognostic Value of Inflammatory Markers in Idiopathic Recurrent Pericarditis

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this